XWELL Inc. Common Stock (XWEL)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a durable business bought at a sensible price. XWELL fails most of my tests. It sells spa and testing services to travelers, a niche with few switching costs and no moat I can identify. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $7.1 million and net income was -$2.2 million, or diluted EPS -$0.26. That followed fiscal Q1 2026, the quarter ended 2026-03-31, with revenue of $6.6 million and a net loss of $11.2 million. For full-year fiscal 2025, ended 2025-12-31, revenue was $29.2 million and net loss was $17.0 million. Sales are shrinking: FairStock calculates revenue growth at -5.48%, and trailing free cash flow is -$13.5 million, a -198.6% FCF yield against a $6.8 million market cap. Balance-sheet risk is severe: debt-to-equity is 0.88, return on equity is -361.36%, Altman Z-score is -33.44, and Piotroski is 3/9. The FairStock score is 14/100, and the Lynch category is none because it has lost money in each of the last four years. At the 2026-10-13 close of $0.79, FairStock calculates P/B at 29.40 and P/E at -0.15; the price is not supported by earnings or book value. This is a speculative turnaround, not a Graham bargain. Until XWELL produces positive free cash flow and consistent profits, the margin of safety is absent.

In plain English: XWELL runs spa and health-testing services for travelers, mostly in airports. The business has lost money for several years, its sales are slipping, and it is burning cash. At 79 cents a share, the price may look low, but the numbers do not show a cheap, healthy company.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer